Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Recurrence 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms, Glandular and Epithelial 1Leukemia, Myeloid, Acute 1Leukemia 1Genital Neoplasms, Female 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Abdominal Neoplasms 1

Interventions

Carboplatin 13Paclitaxel 8Bevacizumab 7Gemcitabine 4130-nm albumin-bound paclitaxel 4liposomal doxorubicin 3relacorilant 2pembrolizumab 2nintedanib 2epothilone B 2Drug Therapy 2Albumin-Bound Paclitaxel 2volociximab 1tremelimumab 1phenoxodiol 1oregovomab 1olaparib 1lanreotide 1farletuzumab 1enzastaurin 1durvalumab 1cc-486 1catumaxomab 1atezolizumab 1Trastuzumab 1Trabectedin 1Topotecan 1Saline Solution 1Oxaliplatin 1Octreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Peritoneal Neoplasms × Cell Count × Clear all
NCT05617755 2025-07-30

AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

Arsenal Biosciences, Inc.

Phase 1 Active not recruiting
19 enrolled
Gynecologic

Abdominal Neoplasms, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡